Attached files
file | filename |
---|---|
EX-99.1 - RADIENT PHARMACEUTICALS Corp | v223102_ex99-1.htm |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 ACT REPORTING REQUIREMENTS
FORM 8-K/A
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
Date of Report (Date of Earliest Event Reported): May 17, 2011
Radient Pharmaceuticals Corporation
(Exact name of registrant as specified in its charter)
Delaware
|
001-16695
|
33-0413161
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
2492 Walnut Avenue, Suite 100, Tustin, California, 92780-7039
(Address of principal executive offices (zip code))
714-505-4461
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))
Section 7 – Regulation FD
Item 7.01 – Regulation FD Disclosure
On May 16, 2011, we filed the initial report on Form 8-K to disclose our settlement with the investors of the Registered Direct Offering we closed in November 2009. We are filing this amendment to file the press release we issued regarding same, which also discloses our filing of a Form 12b-25 regarding our Quarterly Report on Form 10Q for the quarter ended March 31, 2011; such press release is attached as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Exhibit No.
|
Description
|
99.1
|
Press Release
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RADIENT PHARMACEUTICALS CORPORATION
|
||
By:
|
/s/ Akio Ariura
|
|
Name: Akio Ariura
|
||
Title: CFO
|
Dated: May 17, 2011